Benefits
Helps limit uptake of heavy metals eaten at the same time
In a placebo-controlled study of 42 healthy adults, 2 g of purified clinoptilolite swallowed together with a tiny tracer dose of lead cut the lead reaching the blood by about 90 percent. That shows the mineral can trap a metal while both sit in the gut. It does not show removal of metals already stored in the body, and the company behind the product sponsored the work.
Supports bowel comfort, studied in IBS with diarrhea
In a 12-week placebo-controlled pilot of 30 adults with IBS-D taking 2 g three times daily, the main global-relief measure did not beat placebo (21 versus 25 percent responders). Days with clearly less abdominal pain were somewhat more common on zeolite, but the larger drop in diarrhea days (2.4 versus 0.3 a week) could have been chance. A 204-patient everyday-use study reported less pain and bloating, with no comparison group.
Gut barrier marker shifted in endurance athletes
In a placebo-controlled trial, trained athletes taking a zeolite, dolomite and maca capsule for 12 weeks saw stool zonulin fall, while inflammation, oxidation and performance measures did not change. In the IBS-D trial, stool and blood zonulin stayed the same. Independent labs later found that popular commercial zonulin kits, tested in serum, detect other proteins instead, so this is a weak sign of a sturdier gut lining.
Blood lead rose, not fell, in long-term users
In two of three company-linked trials of a clinoptilolite medical device, blood lead ran higher in regular users than in comparison groups, stayed within the reference range, and eased only in the fourth year of an osteoporosis study. The researchers blamed lead released from remodeling bone; leakage from the mineral was not ruled out. Aluminum, nickel and arsenic moved down.
Removal of stored metals is barely tested in people
Marketing presents zeolite as a whole-body cleanser. The main trial showing a fall in serum lead enrolled 80 people with lead poisoning, gave 1 g a day for two weeks and used no placebo. An older report on a liquid clinoptilolite suspension claimed higher urinary metal excretion in healthy people, but it is not indexed in PubMed and could not be checked.
Mechanism of action
Negatively charged cage that swaps cations
Clinoptilolite is a crystalline aluminosilicate whose framework carries a negative charge, balanced by loosely held sodium, potassium, calcium and magnesium in its channels. It trades these for cations it holds more tightly, such as lead and ammonium, and can adsorb some small molecules on its surface.
Works inside the gut, then leaves in stool
The mineral is not absorbed. Whatever it binds in the digestive tract is carried out with it in the stool, so any effect depends on the target and the mineral meeting in the gut at the same time, as in the lead-tracer study. It has no direct access to metals held in bone or organs.
Aluminum and lead are built into the mineral
Aluminum is part of the crystal lattice, and natural deposits can also carry lead. In laboratory tests cited by a safety review, less than 1 percent of bound lead leached out at pH 3 and above but up to 20 percent at pH 1, so acidity matters. Purity and processing also matter, and they differ between brands.
Binding is not selective
Cation exchange does not distinguish toxic metals from useful minerals or from medicines. Long-term users showed drifts in sodium, calcium and copper, and one trial protocol spaced zeolite at least two hours away from other oral drugs to avoid adsorbing them.
Clinical trials
Randomized, double-blind, placebo-controlled parallel-group study using a stable lead-204 tracer (Samekova K, Firbas C, Irrgeher J, et al. 2021, Sci Rep 11(1):14796, PMID 34285282). Sponsored by Glock Health, Science and Research, the company developing G-PUR.
42 healthy adults given G-PUR 2 g, two 2 g doses, or placebo together with 2.5 micrograms of lead-204 in water.
Peak tracer enrichment was 0.505% of total blood lead on placebo versus 0.073% and 0.057% with the two G-PUR regimens, and tracer exposure over 192 hours fell by roughly 90 percent. Urinary tracer excretion also fell, because less lead was absorbed. This shows binding of lead swallowed at the same moment; it does not test removal of lead already in the body. Headache was the most common adverse event and occurred in every group.
Randomized, double-blind, placebo-controlled pilot trial of G-PUR 2 g three times daily for 12 weeks (Anderle K, Wolzt M, Moser G, et al. 2022, World J Gastroenterol 28(46):6573-6588, PMID 36569277). The sponsor, Glock Health, was responsible for the design and report of the study.
30 adults with Rome IV IBS-D (14 on G-PUR, 16 on placebo) after a 4-week run-in.
The primary endpoint was not met: 21% of the G-PUR group and 25% of the placebo group were global-relief responders at 12 weeks. The share of days with at least 30% less abdominal pain favored G-PUR (94% versus 83%), but the drop in diarrhea days (2.4 versus 0.3 a week) and stool-form scores could have been chance. Stool and blood zonulin did not change, and serum aluminum did not rise above normal in anyone. The trial was small and industry-run.
Randomized, double-blind, placebo-controlled trial of Panaceo Sport capsules supplying 1.85 g zeolite a day plus dolomite and maca for 12 weeks (Lamprecht M, Bogner S, Steinbauer K, et al. 2015, J Int Soc Sports Nutr 12:40, PMID 26500463). It was funded by a Panaceo research grant, and Panaceo's research director was a co-author.
52 endurance-trained, non-smoking men and women aged 20 to 50.
Stool zonulin, slightly high at baseline, fell in the zeolite group, and IL-10 tended to rise. Markers of redox status, inflammation and DNA damage, VO2max and maximum performance did not change, and blood minerals including aluminum did not differ between groups. The product was a blend rather than pure clinoptilolite, and the validity of commercial zonulin assays has since been questioned.
Mineral and metal monitoring across three PMA-zeolite trials lasting 28 days, 12 weeks and 4 years (Kraljević Pavelić S, Saftić Martinović L, Simović Medica J, et al. 2022, Front Med (Lausanne) 9:851782, PMID 35712111). Two authors were scientific advisors to Panaceo and one was employed by the company.
Healthy volunteers taking 6 g/day, patients with Crohn's disease taking 6 g/day for 12 weeks, and patients with osteoporosis taking 9 g/day for up to 4 years.
Blood lead was higher in PMA-zeolite users in the short- and long-term studies, stayed within the reference range, and declined in the fourth year; the authors attributed it to lead mobilized from bone. Aluminum and lead did not rise one hour after a dose. Over four years aluminum and nickel fell, while sodium and calcium dropped below reference values in the osteoporosis group and copper dipped before normalizing, prompting advice to check these minerals after a year.
Randomized trial without a placebo, with blinded outcome assessors, of 1 g/day oral zeolite tablets for two weeks (Teimouri S, Deravi N, Khazaei A, et al. 2025, Arch Acad Emerg Med 13(1):e50, PMID 40487907). The tablets were made in-house and the methods describe them only as zeolite. The authors reported no funding and no conflicts of interest.
80 adults in Tehran with serum lead of 20 to 60 mcg/dL and no severe poisoning; about 79% were men.
From similar starting levels (about 45 and 43 mcg/dL), serum lead after two weeks averaged 25.2 mcg/dL with zeolite versus 37.7 mcg/dL with standard care alone, which consisted of removal from exposure and symptom relief. Hematocrit was lower in the zeolite group. Without a placebo and with a single short follow-up, this is an early signal in poisoned patients, not evidence for routine detox use in healthy people.